Laura Prendergast
Stock Analyst at Raymond James
(n/a)
# 4,344
Out of 4,818 analysts
9
Total ratings
12.5%
Success rate
-35.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Initiates: Outperform | $5 | $1.40 | +258.42% | 1 | Mar 26, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Market Perform | n/a | $5.14 | - | 2 | Feb 11, 2025 | |
| MURA Mural Oncology | Initiates: Strong Buy | $18 | $2.64 | +583.11% | 1 | Oct 4, 2024 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $2.19 | +630.59% | 2 | Aug 14, 2024 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | $20 | $1.61 | +1,142.24% | 1 | Jul 31, 2024 | |
| RVMD Revolution Medicines | Upgrades: Strong Buy | $36 → $48 | $38.58 | +24.42% | 2 | Apr 10, 2024 |
Erasca
Mar 26, 2025
Initiates: Outperform
Price Target: $5
Current: $1.40
Upside: +258.42%
Third Harmonic Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $5.14
Upside: -
Mural Oncology
Oct 4, 2024
Initiates: Strong Buy
Price Target: $18
Current: $2.64
Upside: +583.11%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $2.19
Upside: +630.59%
Black Diamond Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: $20
Current: $1.61
Upside: +1,142.24%
Revolution Medicines
Apr 10, 2024
Upgrades: Strong Buy
Price Target: $36 → $48
Current: $38.58
Upside: +24.42%